Skip to main content

Table 1 Comparison of Selected Drugs in Terms of a Response

From: Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

Agent

Splenomegaly1

Anemia2

Symptoms3

References

IMiDs

    

 Thalidomide

19 %

43 %

NS

[15]

 (Celgene Corp., Summit, NJ, USA)

8 %

22 %

NR

[16]

 Lenalidomide

10 %

19 %

NR

[48]

 (Celgene Corp., Summit, NJ, USA)

42 %

30 %

NR

[18]

 Pomalidomide

0

≤40 %

NR

[21]

 (Celgene Corp., Summit, NJ, USA)

11 %

37 %

NR

[22]

0

17 %

NR

[23]

JAK Inhibitors

    

 Ruxolitinib (INCB018424)

44 %

14 %

52–82 %

[42]

 (Incyte Corporation, Wilmington, DE, USA—US rights; Novartis AG, Basel, Switzerland—ex-US rights)

42 %4

NR

46 %5

[43]

32 %5

NR

NR

[44]

 SAR302503 (TG101348) (Sanofi, Paris, France)

39 %

0

25–89 %

[47]

 CYT387 (Cytopia/YM Biosciences, Mississauga, Ontario, Canada)

45

50 %

NR

[49]

 Pacritinib (SB1518) (S*Bio Pte Ltd, Singapore)

44 %

<1 %

NR

[50]

 Lestaurtinib (CEP-701) (Cephalon, Frazer, PA, USA)

18 %

1 %

NR

[51]

mTOR Inhibitor

    

Everolimus (RAD001) (Novartis AG, Basel, Switzerland)

17 %

<1 %

69 %5

[52]

  1. IMiDs = immunomodulatory drugs; NR = not reported; NS = not significant.
  2. 1Percentage of patients achieving ≥50 % reduction in spleen size, unless otherwise specified.
  3. 2Percentage of patients achieving a ≥2 g/dL increase in Hb, unless otherwise specified.
  4. 3Percentage of patients achieving complete resolution of symptoms.
  5. 4Percentage of patients achieving ≥35 % reduction in spleen volume.
  6. 5Percentage of patients achieving ≥50 % reduction in total symptom score on the Myelofibrosis Symptom Assessment Form.